Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.4448
−$0.0052 · -0.15%
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Regular session
$3.4448
−$0.0052 · -0.15%
Regular session · ET · Market data may be delayed.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Day range
Current $3.4448
52-week range
Current $3.4448
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
82
Deep Value
Sentiment
68
Bullish
Risk
60
Elevated Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Day range
Current $3.4448
52-week range
Current $3.4448
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 348.97M USD | 285.5M USD | 198.96M USD | 99.77M USD | 75.44M USD |
| Cost of goods sold | 61.16M USD | 76.6M USD | 62.77M USD | 57.5M USD | 38.86M USD |
| Gross profit | 287.81M USD | 208.9M USD | 136.19M USD | 42.27M USD | 36.59M USD |
| Research and development | 66.35M USD | 45.89M USD | 31.28M USD | 19.72M USD | 12.31M USD |
| Selling, general, and administrative | 144.14M USD | 94.33M USD | 94.31M USD | 91.47M USD | 77.42M USD |
| Operating expenses | 249.01M USD | 136.32M USD | 127.51M USD | 106.38M USD | 83.61M USD |
| Interest income | — | 12.62M USD | 6.15M USD | 2.51M USD | 112K USD |
| Interest expense | 13.83M USD | 37.98M USD | 25.16M USD | 24.77M USD | 16.58M USD |
| Depreciation and amortization | 12.28M USD | 8.97M USD | 5.8M USD | 6.31M USD | 3.24M USD |
| Operating income | 38.8M USD | 72.59M USD | 8.68M USD | −64.11M USD | −47.02M USD |
| Net income | 5.86M USD | 27.59M USD | −11.94M USD | −87.4M USD | −80.93M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.00
190.29% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 3, 2017 | 1:5 | — | — |
Effective Mar 3, 2017
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI37.4M0.00%2.3T USD0.03%$379.45-0.41%
iShares Russell 2000 ETFIWM28.65M0.04%78.56B USD0.19%$274.8-1.05%
State Street SPDR S&P Biotech ETFXBI27.85M0.27%10.08B USD0.35%$147.03-2.13%
Vanguard Extended Market ETFVXF14.36M0.01%95.4B USD0.05%$231.36-0.91%
iShares Russell 2000 Growth ETFIWO10.27M0.07%14.25B USD0.24%$350.57-1.35%
iShares Biotechnology ETFIBB8.01M0.08%10.4B USD0.44%$197.87-2.69%
Vanguard Russell 2000 ETFVTWO7.09M0.04%18B USD0.06%$110.97-1.11%
First Trust Small Cap Growth AlphaDEX FundFYC6.45M0.36%1.36B USD0.70%$112.66-1.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFirst Trust Small Cap Growth AlphaDEX FundFYCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
